Aliskiren/amlodipine/hydrochlorothiazide

Aliskiren/amlodipine/hydrochlorothiazide, sold under the brand name Amturnide, is a fixed-dose combination medication that is used to treat high blood pressure.[1][2] It contains aliskiren, amlodipine, and hydrochlorothiazide.[1] It is taken by mouth.[1]

Aliskiren/amlodipine/hydrochlorothiazide
Combination of
AliskirenRenin inhibitor
AmlodipineCalcium channel blocker
HydrochlorothiazideDiuretic
Clinical data
Trade namesAmturnide
AHFS/Drugs.comMicromedex Detailed Consumer Information
License data
Routes of
administration		By mouth
ATC code
Legal status
Legal status
Identifiers
PubChem CID
KEGG
Chemical and physical data
FormulaC57H86Cl2N8O15S2
Molar mass1258.38 g·mol−1
3D model (JSmol)
SMILES
  • CCOC(=O)C1=C(NC(=C(C1C2=CC=CC=C2Cl)C(=O)OC)C)COCCN.CC(C)C(CC1=CC(=C(C=C1)OC)OCCCOC)CC(C(CC(C(C)C)C(=O)NCC(C)(C)C(=O)N)O)N.C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl
InChI
  • InChI=1S/C30H53N3O6.C20H25ClN2O5.C7H8ClN3O4S2/c1-19(2)22(14-21-10-11-26(38-8)27(15-21)39-13-9-12-37-7)16-24(31)25(34)17-23(20(3)4)28(35)33-18-30(5,6)29(32)36;1-4-28-20(25)18-15(11-27-10-9-22)23-12(2)16(19(24)26-3)17(18)13-7-5-6-8-14(13)21;8-4-1-5-7(2-6(4)16(9,12)13)17(14,15)11-3-10-5/h10-11,15,19-20,22-25,34H,9,12-14,16-18,31H2,1-8H3,(H2,32,36)(H,33,35);5-8,17,23H,4,9-11,22H2,1-3H3;1-2,10-11H,3H2,(H2,9,12,13)/t22-,23+,24-,25-;;/m0../s1
  • Key:YJDDFLDXUPNQTO-WMEHTASQSA-N
  (verify)

It was approved for medical use in the United States in December 2010.[1][3][4] Amturnide was withdrawn by Novartis from the US market in 2017.[5]

References
  1. "Amturnide (aliskiren, amlodipine and hydrochlorothiazide) tablets, for oral use Initial U.S. Approval: 2010". DailyMed. 10 November 2016. Retrieved 6 February 2022.
  2. Neutel JM, Smith DH (October 2013). "Hypertension management: rationale for triple therapy based on mechanisms of action". Cardiovascular Therapeutics. 31 (5): 251–8. doi:10.1111/1755-5922.12015. PMID 23121769.
  3. Amturnide approval letter. U.S. Food and Drug Administration (FDA).
  4. "Drug Approval Package: Amturnide(amlodipine/aliskiren/hydrochlorothiazide) NDA #200045". U.S. Food and Drug Administration (FDA). 15 August 2011. Retrieved 27 August 2020.
  5. Department, the Energy (21 June 2017). "Wyeth Pharmaceuticals Inc. et al.; Withdrawal of Approval of 121 New Drug Applications and 161 Abbreviated New Drug Applications" (PDF). Federal Register. Retrieved 6 February 2022.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.